Ninomiya Yamato, Ozawa Soji, Oguma Junya, Kazuno Akihito, Nitta Miho, Kajiwara Hiroshi, Sato Yasufumi
Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Oncol Lett. 2018 Oct;16(4):5265-5274. doi: 10.3892/ol.2018.9249. Epub 2018 Aug 1.
Vasohibin (VASH) -1 and -2 are novel angiogenic regulators. The aim of the present study was to assess the prognostic values of VASH1 expression and VASH2 expression in esophageal squamous cell carcinoma (ESCC). A total of 209 patients with ESCC were investigated. Resected tumor specimens were immunostained using anti-CD34 antibody, anti-VASH1 antibody and anti-VASH2 antibody. The ratio of the microvessels density and the VASH1 density as the VASH1-positive ratio were defined and the patients were divided into two groups (a high VASH1 group and a low VASH1 group) according to the average value. The patients were also divided into two groups (a high VASH2 group and a low VASH2 group) according to VASH2 expression upon immunostaining. The clinical outcomes of these two groups were then evaluated. The high VASH1 group contained 106 patients (50.7%). The high VASH2 group contained 48 patients (23.0%). Long-term survival was significantly poorer in the high VASH1 group compared with that in the low VASH1 group. A slight correlation between VASH1 expression and VASH2 expression was observed. The low VASH1/low VASH2 group had a better prognosis than the other three groups with different combinations of VASH1 and VASH2 expression levels. The present study showed that high VASH1 expression and high VASH2 expression may be novel independent predictors of a poor prognosis in patients with ESCC and that a slight correlation between VASH1 and VASH2 expression existed. The present findings suggest that combined evaluation of VASH1 and VASH2 expression should provide an improved understanding of their clinicopathological features.
血管抑制素（VASH）-1和-2是新型血管生成调节因子。本研究旨在评估VASH1表达和VASH2表达在食管鳞状细胞癌（ESCC）中的预后价值。共对209例ESCC患者进行了研究。使用抗CD34抗体、抗VASH1抗体和抗VASH2抗体对切除的肿瘤标本进行免疫染色。定义微血管密度与VASH1密度之比即VASH1阳性率，并根据平均值将患者分为两组（高VASH1组和低VASH1组）。还根据免疫染色时的VASH2表达将患者分为两组（高VASH2组和低VASH2组）。然后评估这两组的临床结局。高VASH1组有106例患者（50.7%）。高VASH2组有48例患者（23.0%）。高VASH1组的长期生存率明显低于低VASH1组。观察到VASH1表达与VASH2表达之间存在轻微相关性。低VASH1/低VASH2组的预后优于其他三组VASH1和VASH2表达水平不同组合的患者。本研究表明，高VASH1表达和高VASH2表达可能是ESCC患者预后不良的新型独立预测指标，且VASH1与VASH2表达之间存在轻微相关性。本研究结果表明，联合评估VASH1和VASH2表达应能更好地了解其临床病理特征。
